This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

MannKind Is Still a Risky Investment Even With FDA Approval

Stocks in this article: MNKDLLYSNYNVO

NEW YORK (TheStreet) -- MannKind (MNKD) investors received a healthy dose of good news when the company announced the Food and Drug Administration had finally approved Afrezza, MannKind's inhaled insulin product.

The announcement came late Friday and on Monday investors wasted no time displaying their own brand of approval, sending the stock up roughly 10%. Shares are currently trading around $10.45, up over 100% for the year to date, including gains of 172% since the stock bottomed at $4.02 in April.

Investors are getting too giddy. It's time to lock in gains and move on to the next great idea.

There's no denying this is a huge milestone for the company especially after numerous setbacks. Investors have to remember, however, there are still execution risks MannKind must overcome -- starting with distribution of the product and getting it to market.

Let's assume MannKind does find a commercial partner to get Afrezza into the hands of consumers. There is still no guarantee Afrezza, an alternative to injected insulin, can gain enough traction to make it a business worth pursuing.

>>Ampio Expects Investors to Wear Beer Goggles Before Reading Eye-Drug Press Release

Management has done a great job selling the potential benefits, including the fact that Afrezza limits the need for injections. Still, MannKind is entering an area where there are competing products from dominant and much larger rivals Eli Lilly (LLY) and Sanofi (SNY).

MannKind is certain to have a difficult time separating Afrezza from Lilly's Humalog. Getting FDA approval is a step in the right direction. But the FDA did not allow MannKind to make any sort of claims on its label that suggests Afrezza was a more rapid-acting insulin.

This is a clear distinction from Lilly's Humalog, which was granted FDA permission to make such a claim on its product.

Emails sent to MannKind requesting comment were not immediately returned. But it's worth noting that management has insisted Afrezza is indeed a faster-acting insulin. For now, we'll just have to take the company at its word. But in these cases only the FDA's word should be considered gospel.

There's a small bull case to be made here nonetheless. MannKind has put plenty of resources helping it achieve this small victory. Assuming that management executes through these potential headwinds, MannKind can emerge as clear leader in inhaled insulin.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs